Formulations for cell-schedule dependent anticancer agents

Details Formulations for cell-schedule dependent anticancer agents Formulations for cell-schedule dependent anticancer agents

A - Human Necessities

61

K

A61K 9/00 (2006.01) A61K 47/34 (2006.01) A61P 35/00 (2006.01) A61F 2/02 (2006.01)

Patent

CA 2518791

The present invention provides a flowable composition suitable for use as a controlled release implant. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid; (b) a cell-cycle dependent biological agent, a schedule-dependent biological agent, a metabolite thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble. The present invention also provides a method of treating cancer in a mammal. The present invention also provides a method of blocking, impeding, or otherwise interfering with cell cycle progression at the G1-phase, G1/S interphase, S-phase, G2/M interface or M- phase of the cell cycle in a mammal. The methods includes administering to a mammal an effective amount of a flowable composition of the present invention.

La présente invention concerne une composition fluide pouvant s'utiliser avec un implant à libération contrôlée. Cette composition comprend : (a) un polymère thermoplastique biocompatible, biodégradable, qui est au moins sensiblement insoluble dans un milieu aqueux, dans l'eau ou dans un liquide organique; (b) un agent biologique dépendant du cycle cellulaire ou bien un métabollite ou un sel pharmaceutiquement acceptable ou encore un promédicament de cet agent; et (c) un liquide organique biocompatible, à la température et à la pression normales, dans lequel le polymère thermoplastique est soluble. La présente invention concerne également une méthode de traitement du cancer chez un mammifère. L'invention porte en outre sur une méthode permettant de bloquer, de gêner ou d'entraver la progression du cycle cellulaire à la phase G1, à l'interface G1/S, à la phase S, à l'interface G2/M ou à la phase M du cycle cellulaire chez un mammifère. Ces méthodes consistent à administrer à un mammifère une dose efficace de la composition fluide susmentionnée.

Affiliated with

Also associated with

Rating

Formulations for cell-schedule dependent anticancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulations for cell-schedule dependent anticancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations for cell-schedule dependent anticancer agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1399060